

Alfiyani et al./ Biopsychosocial Determinants of Multi Drug Resistant

Biopsychosocial Determinants of Multi Drug Resistant Tuberculosis in Surakarta

Lina Alfiyani¹⁾, Setyo Sri Rahardjo²⁾, Bhisma Murti¹⁾

¹⁾Masters Program in Public Health, Sebelas Maret University

²⁾Faculty of Medicine, Sebelas Maret University

ABSTRACT

Background: Tuberculosis is an infectious disease that poses serious threat to population health worldwide. Tuberculosis control enterprise becomes more complicated due to increasing number of Multi Drug Resistant Tuberculosis (MDR-TB) cases. Globally there are approximately 580,000 cases of MDR-TB, with only 125,000 cases (20%) resolved. Indonesia ranks tenth in the world by the number of MDR-TB cases after Angola, Azerbaijan, Bangladesh, Belarus, Cina, Korea, Kongo, Etiopia, and India. This study aimed to analyzed the bio-psychosocial determinants of MDR-TB in Surakarta.

Subjects and Method: This was an analytic observational study with case control design. The study was conducted in Dr. Moewardi Hospital and BBKPM, Surakarta, from September to November 2017. A sample consisting of 76 MDR-TB patients and 228 non MDR-TB patients were selected for this study by fixed disease sampling. The dependent variable was MDR-TB. The independent variables were age, drug-taking adherence, depression, comorbidity, drug side-effect, drug-taking supervisor, and family income. The data were collected using a set of questionnaire and analyzed by path analysis.

Results: MDR-TB was affected by lack of drug-taking adherence ($b = -1.7$; 95% CI= -2.23 to -1.07; $p = 0.001$) and comorbidity ($b = 1.5$; 95% CI= 0.76 to 2.30; $p = 0.001$). Drug-taking adherence was affected by depression ($b = -1.7$; 95% CI= -2.60 to -0.79; $p = 0.001$), drug side effect ($b = -1.5$; CI 95%= -2.10 to -0.86; $p = 0.001$), and drug-taking supervisor ($b = 2.5$; 95% CI= 1.84 to 3.06; $p = 0.001$). Comorbidity was affected by age ($b = 0.86$; 95% CI= 0.12 to 1.61; $p = 0.022$).

Conclusion: MDR-TB is directly affected by lack of drug-taking adherence and comorbidity. MDR-TB is indirectly affected by drug-taking supervisor, depression, and drug side effect.

Keyword: bio-psychosocial determinants, MDR-TB

Correspondence:

Lina Alfiyani. Masters Program in Public Health, Sebelas Maret University, Jl. Ir. Sutami 36 A, Surakarta, Central Java. Email: linabbt@gmail.com.

BACKGROUND

Tuberculosis (TB) is one of the infectious diseases as the most leading to death in cases of tuberculosis with HIV comorbidities (Falzon et al., 2013). Tuberculosis is among the top 10 diseases causing death in the world with 1.4 million deaths annually (Petrucchioli et al., 2016). The highest case of tuberculosis in 2015 comes from Southeast Asia (45.6%) of the world's population, and Indonesia ranks 2 out of 11 countries after India (23%) with the percentage of 10%, namely 1020 cases per

1000 population with the highest burden of tuberculosis (WHO, 2016a).

Another fundamental issue other than the case of death is the economic problem. The decrease in productivity in patients becomes a problem that needs to be considered. The high cases of tuberculosis and the emergence of economic problems are becoming public health problems in the world especially in developing countries including Indonesia (Sulistiyan et al., 2015).

High tuberculosis cases are difficult to detect and reduce, it is due to the medical and non-medical problems, which include medical problems such as the nature of tuberculosis as a chronic disease, inadequate use of anti-tuberculosis (OAT) drugs, immunodepression, age ≥ 35 years, diabetes mellitus and the occurrence of ESO, whereas non-medical problems include poverty, low education, low support of PMO and delayed diagnosis (Zhang et al., 2016). Amita and Pratima (2008) explain that genetic factors, incomplete treatment and treatment adherence, microbiology, clinical factors, HIV / AIDS, programs and germs affect MDR-TB (Hirpa et al., 2013).

WHO recommends Isoniazid and rifampicin as effective drugs for the first-line treatment. Therefore, resistance to both drugs has become a serious threat (Mekonnen et al., 2015). WHO (2017) mentions in the handling of MDR-TB sustained crisis detection. Globally, 580,000 cases of tuberculosis have MDR-TB, with 125,000 (20%) cases were resolved. Indonesia was one of the worst crisis in the world and ranked tenth in the world (WHO, 2016b). 45% of the cases of detectable and potentiated MDR-TB needed to improve tuberculosis detection and early identification of MDR-TB as key to solve the problem (Prosser et al., 2016).

Data on MDR-TB cases in Indonesia in 2015 display that there were 15,380 cases, 1,860 confirmed cases and 1,566 cases treated. 17 provinces in Indonesia have success rate of tuberculosis treatment $< 85\%$, one of them is Central Java Province (Ministry of Health, 2016). The case of tuberculosis in Surakarta was in the third highest in Central Java Province with case notification rate (CNR) in 2016 of 85 per 100,000 population (Central Java Provincial Health Office, 2016). Based on preliminary study, in 2015, MDR-TB clinic

visit reached 1839. In 2016, it reached 1793 and in 2017 it reached 1466 visit (period of January-May). The number of visits in 2017 was likely to increase again until the December period. In addition to the preliminary study results in BBKPM Surakarta, the data about treatment for 189 patients were found out.

WHO recommends Directly Observed Treatment Shortcourse (DOTS) strategy as an effort to manage MDR-TB able to give hope for the success of MDR-TB case treatment (Abubakar et al., 2013). On time diagnosis of MDR-TB, particularly among new tuberculosis cases, is important to facilitate appropriate treatment, thus preventing the emergence of advanced drug resistance and its spread in the population (Atre, 2015).

The high prevalence of MDR-TB indicates that the problem is an urgent that must be resolved by using an approach model capable of assessing various factors, either directly or indirectly. This study used a biopsychosocial model approach to assess the determinants based on causation and risk factors for MDR-TB both biologically, psychologically and socially.

Based on the background, the author was interested to analyze Biopsychosocial Determinants of Multi Drug Resistant Tuberculosis in Surakarta.

SUBJECTS AND METHOD

1. Study design

This was a case control study. The study was conducted in Dr. Moewardi hospital and BBKPM Surakarta, from September to November 2017.

2. Population and sample

The target population was all tuberculosis and MDR-TB patients. The case population was MDR-TB patients in Dr. Moewardi hospital. While the control population was tuberculosis patients in BBKPM Surakarta.

The sampling technique was fixed disease sampling with a large sample of 304 research subjects using a ratio of 1: 3. The number of case samples was 76 MDR-TB patients and the control samples were 228 tuberculosis patients.

The inclusion criteria were subjects aged ≥ 15 years old and able to fill the questionnaire well. While the exclusion criteria of patients were those who experience psychiatric disorders.

3. Study variables

The independent variables were family income, depression, drug side effects, drug taking advisor, adherence, age, comorbidity and the dependent variable was MDR-TB.

4. Operational definition of variables

MDR-TB was defined as tuberculosis patients diagnosed with MDR-TB because *Mycobacterium tuberculosis* is resistant to two first-line anti-tuberculosis drugs namely rifampicin and isoniazid, and the measurement tool is X-pert MTB / RIF measurements in medical records. The measurement scale was categorical, coded 0 for no MDR TB and 1 for MDR TB.

Drug side effect was defined as the reaction of drug as a result of the treatment of tuberculosis. The data were collected by questionnaire. The measurement scale was categorical, coded 0 for no drug side effect and 1 for drug side effect.

The drug taking advisor support was defined a person who is in charge of ensuring regularity or medication adherence during the patient's treatment period. The data were collected by questionnaire. The measurement scale was categorical, coded 0 for weak support and 1 for strong support.

Depression was defined an emotional disturbance in patients where patients experience panic, stress, irritability, and fear. The data were collected by questionnaire. The measurement scale was conti-

nuous, but for the purpose of data analysis, it was transformed into dichotomous, coded 0 for low stress and 1 for high stress.

Drug taking adherence was defined as a condition that describes patient obedience in taking the appropriate medications based on health personnel instruction. The data were collected by questionnaire. The measurement scale was continuous, but for the purpose data analysis, transformed into dichotomous, coded 0 for drug taking irregularly and 1 for drug taking regularly.

Family income was defined as the average income during the last 6 months as a result of the economic process or cumulative economic resources of the whole family members (husband, wife, and children). The data were collected by questionnaire. The measurement scale was continuous, but for the purpose data analysis, transformed into dichotomous, coded 0 for low family income and 1 for high family income.

Age was defined as the age of the subjects from the birth to the time the study was conducted. The data were collected by questionnaire. The measurement scale was continuous, but for the purpose data analysis, transformed into dichotomous, coded 0 for younger age and 1 for older age.

Comorbidity was defined as the presence of one or more other diseases that accompanied tuberculosis. The data were collected by questionnaire. The measurement scale was categorical, coded 0 for without co-morbidity and 1 for with co-morbidity.

5. Data analysis

The data analysis of the study used path analysis to determine the magnitude of the influence of variables, either the directly or indirect influences. The pathway analysis steps are model specification, model

identification, model conformity, parameter estimation and model respecification.

6. Research Ethics

The research ethical clearance was granted from the Research Ethics Committee at Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia. Research ethics included issues such as informed consent, anonymity, confidentiality, and ethical clearance.

RESULTS

1. Sample Characteristics

Table 1 shows the sample characteristics. As many as 137 study subjects (85.1%) were smoker.

Table 1. The Distribution of Research Subjects

No	Characteristics	Case		Control	
		N	%	N	%
1.	Gender				
	Male	50	29.1	122	70.9
	Female	26	19.7	106	80.3
2.	Education				
	Low	43	28.7	107	71.3
	High	33	21.4	121	78.6
3.	Occupation				
	Working at house	13	19.4	54	80.6
	Working outside the house	63	26.6	174	73.4
4.	Marital Status				
	Unmarried	11	21.6	40	78.4
	Married	65	25.7	188	74.3
5.	Smoking				
	Smoking	52	36.4	91	63.6
	Not smoking	24	14.9	137	85.1
6.	Alcohol				
	Alcohol	22	40.0	33	60.0
	No Alcohol	54	21.7	195	78.3
7.	Contact				
	Contact	18	43.9	23	56.1
	No Contact	58	22.1	205	77.9

2. Pathway Analysis

The results of the study were analyzed using STATA 13. The steps of pathway analysis were model specifications, model identification, parameter estimation and model respecification. The number of

The characteristics of subjects in relation to alcohol habit, in the case group, almost all subjects did not have a habit of alcohol (58 subjects/71.1%). This is similar to the control group with 195 subjects (85.5%).

The last characteristic is related to the tuberculosis contact. Most of the subjects did not know about tuberculosis contacts (58 subjects /76.3%) in the case group. Then, in the control group, almost all subjects were entirely unaware of tuberculosis contacts (205 subjects/89.9%).

measured variables was 8, endogenous variables (4), and exogenous variables (4). So, the degree of freedom (df) was 20. Then, it can be concluded that df was over identified which means that the path analysis can be done.




Figure 2. Structural Model with Estimate

The structural model with estimates shown in Figure 2 and the results of the analysis of the biopsychosocial pathways of MDR-TB were presented in Table 3. The models in this study were in accordance with the sample data as indicated by the saturation

model and also the regression coefficients of more than zero and statistically significant, it is not necessary to recreate the path analysis model because it has obtained the model according to the sample data.

Table 3. The result of path analysis on the biopsychosocial determinant of Multi Drug Resistant Tuberculosis

Drug-Resistant Tuberculosis						
Dependent Variabel		Independent Variable	b	95% CI		p
				Lower Limit	Upper Limit	
Direct Effect						
MDR-TB	←	Drug taking (adherence)	-1.7	-2.23	-1.06	0.001
	←	Comorbidities	1.5	0.76	2.30	0.001
Indirect Effect						
Adherence	←	Drug Side Effects	-1.5	-2.10	-0.89	0.001
	←	Drug taking advisor	2.5	1.84	3.07	0.001
Depresi	←	Depression	-1.7	-2.60	-0.79	0.001
	←	Family income	-1.1	-2.04	-0.23	0.014
	←	Drug Side Effects	0.7	-0.14	1.31	0.055
Comorbidities	←	Age	0.86	0.12	1.61	0.022
N observation = 304						
Log Likelihood= -508.40						

Table 3 shows the result of path analysis on the biopsychosocial determinant of Multi Drug Resistant Tuberculosis. Table 3 shows that adherence in drug taking ($b = -1.7$; 95% CI = -2.23 to -1.07; $p = 0.001$) decreased the risk of MDR-TB occurrence.

Comorbidities increased the risk of MDR-TB occurrence ($b = 1.5$; 95% CI = 0.76 to 2.30; $p = 0.001$).

Severe depression ($b = -1.7$; 95% CI = -2.60 to -0.79; $p = 0.001$) and drug taking effect ($b = -1.5$; 95% CI = -2.10 to -0.86; $p = 0.001$) lowered the drug taking adherence.

Support from drug taking advisor ($b = 2.5$; 95% CI = 1.84 to 3.06; $p = 0.001$) improved the drug taking adherence.

High family income decreased depression ($b = -1.1$; 95% CI = -2.04 to -0.23; $p = 0.014$).

Drug side effect increased depression ($b = 0.65$; 95% CI = -0.14 to 1.13; $p = 0.055$).

Aged ≥ 40 years increased the likelihood of comorbidity ($b = 0.87$; 95% CI = 0.12 to 1.61; $p = 0.022$).

DISCUSSION

1. The association between drug taking adherence and MDR-TB

The result of this study showed that drug-taking adherence decreased the risk of MDR-TB. This study is supported by Cuevas and Pe (2015), it is showed that patients who had low adherence during treatment would increase the risk of MDR-TB by 2 times compared to the patients with high adherence to tuberculosis. The mechanism of MDR-TB occurrence is associated to drug failure in affecting the germs, or germs that do not absorb OAT. Bhunia et al. (2015) explains that the behavioral changing from sensitive to resistant due to lack of treatment usually occurs within a few weeks after the start of treatment with different time of the occurrence of resistance in each individual. Patients' obedience in the treatment greatly affects the success of treatment. The result of this study showed that MDR-TB is more prevalent in subjects of non-adherence to treatment than the subjects who are obedient in doing the treatment. Fagundez et al. (2016) explained that irregular follow-up of tuberculosis causes a person to have 3 times higher risk for MDR-TB than a patient who conducts the follow up routinely, this is in line with a study by Aderita Aderita et al. (2016) which showed

that low-compliance tuberculosis patients had 4 times higher risk for MDR-TB.

2. The association between comorbidity and MDR-TB

The result of this study showed that comorbidity increase the risk of MDR-TB. Diabetes mellitus (DM) is one of the most common comorbidities in tuberculosis cases (Magee et al., 2013). Navarro et al. (2015) explains that type 2 of DM comorbidities in TB cases leads to a decrease in the immune system, which is associated with poor blood sugar control, leading to impaired phagocytosis, chemotaxis, reactive oxygen species (ROS), and Th_{17} cell function. In addition, Baghaei et al. (2015) stated that the immune response disorders in TB patients with DM may increase the risk of resistant strains of infection, and it leads to MDR-TB.

Based on the research by Mohd et al. (2015), it is showed that assessing the conversion in TB patients with DM after two to three months of TB therapy had 7 times higher risk for no convention. The possibility of more severe infections, more mycobacterial charges, longer convention times, and longer treatment in TB patients with DM are more likely to be resistant to TB. According to Viswanathan et al. (2014), BTA smear in patients with DM remained positive in the second month of treatment, it is an important risk factor for the transmission of resistance.

WHO describes the association of TB and DM is that the patients have 4 times higher risk of death, plasma OAT concentrations lower than non-DM patients, therefore, it leads to the risk of treatment failure (OAT resistance) and poor glycemic control which can interfere the DM treatment through drug interactions, and the disruption of certain OAT activities (Ministry of Health, 2015).

3. The association between depression and MDR-TB through drug taking adherence

The result of this study showed that depression increase the risk of MDR-TB. Depression can affect the disobedience of treatment, the depression can increase the risk of morbidity and mortality as a result of TB disease (Duko *et al.*, 2015). Early diagnosis of TB disease becomes one of the stressors that cause psychological disorders especially depression and become one of the factors that can affect the treatment process (Pachi *et al.*, 2013). Depression experienced by tuberculosis sufferers often causes the obstruction in the treatment process. The causes of increased depression are associated with misconceptions about disease and long treatment (Peddireddy, 2016). Depression that occurs will affect the decrease of body resistance to infection and affect the adherence of tuberculosis patients in doing tuberculosis treatment process, therefore, it slows the healing process and increases the risk of MDR-TB (Theron *et al.*, 2015).

4. The association between drug taking advisor and MDR-TB through adherence

DOTS program is used as an effort to control tuberculosis to ensure short-term treatment of patients can be resolved properly, in addition, DOTS program can affect the drug-taking adherence (Ministry of Health, 2014). One of the DOTS components is the OAT treatment with direct supervision/DSC (Vijay *et al.*, 2010). Based on the research by Septia *et al.* (2013) it can be seen that big support from DSC has an effect on the enhancement of adherence. He (2016) explained that motivation and support from DSC can help in increasing the willingness of tuberculosis patients to recover by doing the treatment regularly until it is done.

Routine Follow-up is necessary to maintain the regularity in taking anti-tuberculosis drugs, it is necessary for DSC to always monitor the treatment of tuberculosis patients (Akshata and Chakrabarty, 2016), besides that, if tuberculosis patients do the treatment regularly, it will reduce the risk of increasing the disease and prevent the transmission of tuberculosis disease to others (Thi *et al.*, 2015).

5. The association between drug side effect and MDR-TB through drug taking adherence

The result of this study showed that DSE increase the risk of MDR-TB. According to Zhang *et al.* (2016), DSE affects medication adherence and impacts on drop out treatment. Woimo *et al.* (2017) stated that the lower the side effects that appear the higher the medication adherence. In addition, the treatment period that takes a long time and it leads to DSE, therefore, it causes the patient to stop taking the medicine (Gao *et al.*, 2016).

6. The association between family income and MDR-TB through depression and adherence

The result of this study showed that family income decrease the risk of MDR-TB through depression and adherence. According to a study by Liu *et al.* (2015), it is stated that social economy becomes one of the factors that influence the tuberculosis. Another problem that occurs in the case of tuberculosis other than death is the fundamental problem which is economic problems both from government and individuals, therefore the decrease of productivity in tuberculosis sufferer becomes a problem that need to be solved.

Financial life is highly dependent on someone's ability to work. If she/he is no longer productive and she/he has physical weakness caused by tuberculosis disease, it can lead to decreased work productivity

(Ambaw *et al.*, 2015). Depression in tuberculosis patients is also associated with many factors, such as age, sex, socioeconomic status, changes in social relations and stigmatization of tuberculosis (Koyanagi *et al.*, 2017). Economic problems, stigma and social support become one of the factors that affect the depression in patients with tuberculosis (Duko *et al.*, 2015). Thomas *et al.* (2016) stated that risk factors that affect the development of various psychiatric disorders is related to low socioeconomic status. This in accordance with the results of this study which indicates that family income increases the risk of MDR-TB through depression.

7. The association between drug side effect and MDR-TB through depression and adherence

The result of this study showed that DSE increase the risk of MDR-TB through depression and adherence. WHO defines ADRs as response to a drug, unintentionally or undesirably and occurs at doses that commonly used for the prevention, diagnosis or treatment of disease (Koyanagi *et al.*, 2017). The high prevalence of psychiatric problems, especially depression as well as the presence of psychological reactions related to the perception of disease shows that psychological complications have a side effect of tuberculosis treatment (Farazi *et al.*, 2014). One of the side effects obtained by tuberculosis treatment is the physical effects that cause the disruption of the work and or may affect the social role of the sufferer (Sulehri *et al.*, 2012).

Koyanagi *et al.* (2017) explains that the factors that may affect the depression in patients with tuberculosis are age ≥ 32 years old, male gender, tuberculosis diagnosis, drug side effects, low socioeconomic and comorbidities. Marra *et al.* (2014), explained that the decrease in the quality of life in

patients with tuberculosis due to depression caused by many related aspects such as the existence of long-term therapy, social stigma associated with tuberculosis, lack of patient knowledge about disease, tuberculosis treatment process, and adverse reactions (drug side effects) in most tuberculosis patients.

8. The association between age and MDR-TB through comorbidity

The result of this study showed that age increase the risk of MDR-TB through comorbidity. Physiological function of the body will decrease at older age (≥ 60 years old) and along with the enhancement of age can lead to atherosclerosis and macroangiopathy disorder that affect the decrease of blood circulation so that it can lead to the occurrence of diseases such as diabetes mellitus and hypertension (Young *et al.*, 2009). In some studies, it has been found that there is a significant relationship between age and OAT resistance with higher proportion of MDR-TB among the 45-64 years old group, in addition, the DM comorbidities in older TB patients increases the risk of MDR-TB, because in the elderly, the decrease in the immune system leads to physical inability to fight TB bacilli thus increasing the risk of MDR-TB (Wahyuni *et al.*, 2016). Similar to Tao *et al.* (2017) which stated that a person with diabetes and HIV/AIDS aged ≥ 45 years has 2 times higher risk of having MDR-TB due to a low immune system and decreased body function. Aibana *et al.* (2017) explains that the older the person, the lower the immunity in the body, and the older age groups are more exposed to other risk factors such as alcohol, cigarette smoke and infectious diseases.

Based on the result of this study, it can be concluded that the risk of MDR-TB decrease by the enhancement of drug-taking adherence, the support from DSC

and family income. The risk of MDR-TB is increased by the enhancement of comorbidity, depression, DSE and age.

REFERENCE

- Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I *et al.* (2013). Tuberculosis 2013: 5 Drug-resistant tuberculosis: Time For Visionary Political Leadership. *Lancet Infect Dis.* 13: 529–539.
- Aderita NI, Murti B, Suryani N (2016). Risk Factors Affecting Multi-Drug Resistant Tuberculosis in Surakarta and Wonogiri, Central Java, Indonesia. *Journal of Health Promotion and Behavior*, 1: 88–101.
- Aibana O, Bachmaha M, Krasiuk V, Rybak N, Flanigan TP, Petrenko V, Murray MB (2017). Risk Factors for Poor Multidrug-Resistant Tuberculosis Treatment Outcomes in Kyiv. *BMC Infectious Diseases*, 17: 1–7.
- Akshata JS, Chakrabarthy A (2016). Management of Multidrug Resistant Tuberculosis (MDR-TB) – Monitoring is the Key to Successful Outcome. *Egyptian Journal of Chest Diseases and Tuberculosis*, 65(2): 447–450.
- Ambaw F, Mayston R, Hanlon C, Alem A (2015). Depression among Patients with Tuberculosis: Determinants, Course and Impact on Pathways to Care and Treatment Outcomes in a Primary Care Setting in Southern Ethiopia—a Study Protocol. *BMJ Open*, 5: 1–10.
- Amita J, Pratima D (2008). Multidrug Resistant to Extensively Drug Resistant Tuberculosis: What is Next? (Special Issue. Emerging and Re-Emerging Infections in India). *Journal of Biosciences*, 33: 605–616.
- Atre S (2015). An Urgent Need for Building Technical Capacity for Rapid Diagnosis of Multidrug-Resistant Tuberculosis (MDR-TB) Among New Cases: a Case Report from Maharashtra, India. *Journal of Infection and Public Health*, 8(5): 502–505.
- Baghaei P, Tabarsi P, Moniri A, Marjani M, Velayati AA (2015). Impact of Diabetes Mellitus on Tuberculosis Drug Resistance in New Cases of Tuberculosis. *International Journal of Mycobacteriology*, 4: 128.
- Bhunias SK., Sarkar M, Banerjee A, Giri B (2015). An Update on Pathogenesis and Management of Tuberculosis with Special Reference to Drug Resistance. *Asian Pacific Journal of Tropical Disease*, 5(9): 673–686.
- Cuevas CD, Pe W (2015). Psychometric Properties of the Eight-Item Morisky Medication Adherence Scale (MMAS-8) in a Psychiatric Inpatient. *International Journal of Clinical and Health Psychology*, 15: 121–129.
- Dinas Kesehatan Provinsi Jawa Tengah (2016). *Buku Saku Kesehatan Triwulan 2 tahun 2016*. Semarang: Dinas Kesehatan Provinsi Jawa Tengah.
- Duko B, Gebeyehu A, Ayano G (2015). Prevalence and Correlates of Depression and Anxiety Among Patients with Tuberculosis at Wolaitasodo University Hospital and Sodo Health Center, Wolaitasodo, South Ethiopia, Cross. *BMC Psychiatry*, 1–7.
- Fagundes G, Freixo HP, Eyene J, Carlos-Momo J, Biye L, Esono T, Marcial OM *et al.* (2016). Treatment Adherence of Tuberculosis Patients Attending Two Reference Units in Equatorial Guinea. *PLoS ONE*, 11 (9): e0161995.
- Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione MC (2013). Universal Access to Care for Multidrug-Resistant Tuberculosis: an Analysis of Surveillance Data. *The Lancet Infectious Diseases*, 13(12): 1000–1008.

- ous Diseases, 13(8): 690–697.
- Farazi A, Sofian M, Jabbariasl M, Keshavarz S (2014). Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients. *Tuberculosis Research and Treatment*, 1–6.
- Gao J, Ma Y, Du J, Zhu G, Tan S, Fu Y, Ma L *et al.* (2016). Later Emergence of Acquired Drug Resistance and its Effect on Treatment Outcome in Patients Treated with Standard Short-Course Chemotherapy for Tuberculosis. *BMC Pulmonary Medicine*, 16:26.
- He T (2016). Social Support Received by Multidrug-Resistant Tuberculosis Patients and Related Factors: a Cross-Sectional Study in Zhejiang Province, People's Republic of China. *Patient Preference and Adherence*, 10: 1063–1070.
- Hirpa S, Medhin G, Girma B, Melese M, Mekonen A, Suarez P (2013). Determinants of Multidrug-Resistant Tuberculosis in Patients Who Underwent First-Line Treatment in Addis Ababa: a Case Control Study. *BMC Public Health*, 13(1): 1.
- Kemenkes RI (2014). *Strategi Nasional Pengendalian TB*. Jakarta: Kemenkes RI.
- _____ (2015). *Buku Petunjuk Teknis Penemuan Pasien TB-DM di Fasilitas Kesehatan Rujukan*. Jakarta: Kemenkes RI.
- _____ (2016). *InfoDatin-2016-TB*. Jakarta: Kemenkes RI.
- Koyanagi A, Vancampfort D, Carvalho AF, DeVlyder JE, Haro JM, Pizzo D, Veronese N *et al.* (2017). Depression Comorbid with Tuberculosis and its Impact on Health Status: Cross-Sectional Analysis of Community-Based Data From 48 Low- and Middle-Income Countries. *BMC Medicine*, 15(1): 1–10.
- Liu YX, Pang CK, Liu Y, Sun X, Bin, Li XX, Jiang S *et al.* (2015). Association Multidrug-Resistant Tuberculosis and Risk Factors in China: Applying Partial Least Squares Path Modeling. *PLoS ONE*, 10(5): 1–14.
- Magee MJ, Bloss E, Shin SS, Contreras C, Huamane HA, Ticona JC, Bayona J *et al.* (2013). International Journal of Infectious Diseases Clinical Characteristics, Drug Resistance, and Treatment Outcomes among Tuberculosis Patients with Diabetes in Peru. *International Journal of Infectious Diseases*, 17(6): 404–e412.
- Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G (2015). Multidrug Resistant Tuberculosis: Prevalence and Risk Factors in Districts of Metema and West Armachiho, Northwest Ethiopia. *BMC Infectious Diseases*, 2–7.
- Mohd N, Azhar S, Kamaludin F (2015). The Risk Factors of Multidrug-Resistant Tuberculosis among Malaysians. *International Journal of Mycobacteriology*, 5(1): 51–58.
- Navarro LM, Fuentes FJ, Zenteno CR (2015). Type 2 Diabetes Mellitus and its Influence in the Development of Multidrug Resistance Tuberculosis in Patients From Southeastern Mexico. *Journal of Diabetes and its Complications*, 29(1): 77–82.
- Pachi A, Bratis D, Moussas G, Tselebis A (2013). Psychiatric Morbidity and Other Factors Affecting Treatment Adherence in Pulmonary Tuberculosis Patients. *Tuberculosis Research and Treatment*.
- Peddireddy V (2016). Quality of Life, Psychological Interventions and Treatment Outcome in Tuberculosis Pa-

- tients: the Indian Scenario Psychological Distress in Tuberculosis. *Frontiers in Psychology*, 1–9.
- Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G, Barcellini L *et al.* (2016). Characterization of The CD4 and CD8 T-Cell Responses to Quantiferon-TB Plus. *Journal of Infection*, 73(6): 588–597.
- Prosser G, Brandenburg J, Reiling N, Barry CE, Wilkinson RJ, Wilkinson KA (2016). The Bacillary and Macrophage Response to Hypoxia in Tuberculosis and the Consequences for T Cell Antigen Recognition., *Microbes and infection*, 1–16.
- Septia A, Rahmalia S, Sabrian F (2013). Hubungan Dukungan Keluarga dengan Kepatuhan Minum Obat pada Penderita TB Paru. *JOM Psikology*, 1–10.
- Sulistiyani, Wahjono H, Sabdono A, Khoeri MM, Karyana E (2015). Antimycobacterial Activities from Seagrass *Enhalus* sp. Associated Bacteria Against Multi Drug Resistance Tuberculosis (MDR TB) Bacteria. *Procedia Environmental Sciences*, 23:253–259.
- Tao N, He X, Zhang X, Liu Y, Yu C, Li H (2017). International Journal of Infectious Diseases Trends and Characteristics of Drug-Resistant Tuberculosis in Rural. *International Journal of Infectious Diseases*, 65: 8–14.
- Theron G, Peter J, Zijenah L, Chanda D, Mangu C, Clowes P, Rachow A *et al.* (2015). Psychological Distress and its Relationship with Non-Adherence to TB Treatment: a Multicentre Study. *BMC Infectious Diseases*, 13–19.
- Thi TH, Nguyen NV, Dinh SN, Nguyen HB, Cobelens F, Thwaites G, Nguyen HT *et al.* (2015). Challenges in Detection and Treatment of Multidrug Resistant Tuberculosis Patients in Vietnam. *BMC Public Health*, 1–10.
- Thomas BE, Shanmugam P, Malaisamy M, Ovung S, Suresh C, Subbaraman R, Adinarayanan S (2016). Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: a Systematic Review. *PLoS ONE*, 1–15.
- Vijay S, Kumar P, Chauhan LS, Hanumanthappa B, Kizhakkethil UP, Rao SG (2010). Risk Factors Associated with Default among New Smear Positive TB Patients Treated Under DOTS in India. *Tuberculosis Research and Treatment*, 5(4).
- Viswanathan V, Vigneswari A, Selvan K, Satyavani K, Rajeswari R, Kapur A (2014). Journal of Diabetes and its Complications Effect of Diabetes on Treatment Outcome of Smear-Positive Pulmonary tuberculosis-A report from South India. *Journal of Diabetes and Its Complications*, 28(2): 162–165.
- Wahyuni M, Amir Z, Yunita R, Rahardjo W, Abidin A, Malik AR (2016). Pengaruh Merokok Terhadap Konversi Sputum pada Penderita Tuberkulosis Paru Kategori I. *J Respir Indo*, 36(2): 106–112.
- WHO (2016a). Global Report Tuberculosis Report 2016. Geneva: WHO Press.
- _____ (2016b). World Health Statistics SDG s. Geneva: WHO Press.
- _____ (2017). Global Tuberculosis Report 2017. Geneva: WHO Press.
- Woimo TT, Yimer WK, Bati T, Gesesew HA (2017). The Prevalence and Factors Associated for Anti-Tuberculosis Treatment Non-Adherence among Pulmonary Tuberculosis Patients in Public Health Care Facilities in South Ethiopia: a Cross-Sectional Study. *BMC Public Health*, 17(1): 269.
- Young F, Critchley JA, Johnstone LK,

Unwin NC (2009). Globalization And Health aReview of Co-Morbidity Between Infectious and Chronic Disease in Sub Saharan Africa : TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the Impact of Globali-

zation. BMC Public Health, 9: 1–9.
Zhang C, Wang Y, Shi G, Han W, Zhao H, Zhang H (2016). Determinants of Multidrug-Resistant Tuberculosis in Henan Province China: a Case Control Study. BMC Public Health, 1–8.